Document is current

Article History

Received: 17 December 2022

Accepted: 27 March 2023

First Online: 8 April 2023

Declarations

:

: D. Takahari reports funding and honoraria from Taiho Pharmaceutical, and provision of study materials from Taiho Pharmaceutical and Yakult Honsha. A. Takashima reports honoraria from Taiho Pharmaceutical. N. Izawa reports funding, research grant and honoraria from Taiho Pharmaceutical. K. Chin reports honoraria from Taiho Pharmaceutical. S. Iwasa reports research grant and honoraria from Taiho Pharmaceutical. H. Shoji reports an advisory role at Ono Pharmaceutical, and other financial interests at Astellas, Ono Pharmaceutical, Daiichi Sankyo, MSD, and Amgen. T. Yoshikawa reports honoraria from Taiho Pharmaceutical and Chugai. T. Sano reports honoraria from Taiho Pharmaceutical N. Boku reports funding from Taiho Pharmaceutical and Yakult, and research grants from Ono Pharmaceutical and Takeda, and honoraria from Taiho Pharmaceutical, Ono Pharmaceutical, Daiichi-Sankyo, and BMS. K. Yamaguchi reports funding from Ono Pharmaceutical, and honoraria from Ono Pharmaceutical and BMS. All other authors declare no competing interests.

: All procedures followed were in accordance with the ethical standards of the institutional and national committees governing human experimentation and in compliance with the Helsinki Declaration of 1964 and later versions.

: Informed consent or an appropriate substitute was obtained from all patients prior to their inclusion in the study.